|
Gene: NDUFAB1 |
Gene summary for NDUFAB1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NDUFAB1 | Gene ID | 4706 |
Gene name | NADH:ubiquinone oxidoreductase subunit AB1 | |
Gene Alias | ACP | |
Cytomap | 16p12.2 | |
Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | O14561 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4706 | NDUFAB1 | GSM4909282 | Human | Breast | IDC | 3.17e-17 | 4.94e-01 | -0.0288 |
4706 | NDUFAB1 | GSM4909285 | Human | Breast | IDC | 1.06e-02 | 3.32e-01 | 0.21 |
4706 | NDUFAB1 | GSM4909290 | Human | Breast | IDC | 1.47e-05 | 3.34e-01 | 0.2096 |
4706 | NDUFAB1 | GSM4909291 | Human | Breast | IDC | 1.02e-02 | 2.29e-01 | 0.1753 |
4706 | NDUFAB1 | GSM4909293 | Human | Breast | IDC | 4.66e-05 | 3.12e-01 | 0.1581 |
4706 | NDUFAB1 | GSM4909294 | Human | Breast | IDC | 2.35e-08 | 2.88e-01 | 0.2022 |
4706 | NDUFAB1 | GSM4909296 | Human | Breast | IDC | 6.52e-13 | 1.77e-01 | 0.1524 |
4706 | NDUFAB1 | GSM4909297 | Human | Breast | IDC | 6.05e-11 | -1.08e-01 | 0.1517 |
4706 | NDUFAB1 | GSM4909298 | Human | Breast | IDC | 2.92e-03 | 3.03e-01 | 0.1551 |
4706 | NDUFAB1 | GSM4909301 | Human | Breast | IDC | 1.45e-03 | 2.27e-01 | 0.1577 |
4706 | NDUFAB1 | GSM4909304 | Human | Breast | IDC | 7.12e-04 | 3.82e-01 | 0.1636 |
4706 | NDUFAB1 | GSM4909306 | Human | Breast | IDC | 4.03e-29 | 6.71e-01 | 0.1564 |
4706 | NDUFAB1 | GSM4909307 | Human | Breast | IDC | 1.63e-04 | 3.02e-01 | 0.1569 |
4706 | NDUFAB1 | GSM4909308 | Human | Breast | IDC | 1.87e-15 | 4.27e-01 | 0.158 |
4706 | NDUFAB1 | GSM4909309 | Human | Breast | IDC | 2.35e-03 | 5.61e-02 | 0.0483 |
4706 | NDUFAB1 | GSM4909311 | Human | Breast | IDC | 5.04e-42 | -1.57e-01 | 0.1534 |
4706 | NDUFAB1 | GSM4909312 | Human | Breast | IDC | 1.46e-11 | 2.08e-02 | 0.1552 |
4706 | NDUFAB1 | GSM4909316 | Human | Breast | IDC | 3.55e-07 | 2.83e-01 | 0.21 |
4706 | NDUFAB1 | GSM4909318 | Human | Breast | IDC | 6.18e-05 | 3.47e-01 | 0.2031 |
4706 | NDUFAB1 | GSM4909319 | Human | Breast | IDC | 5.17e-49 | -1.40e-01 | 0.1563 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00460349 | Breast | Precancer | ATP metabolic process | 82/1080 | 277/18723 | 1.94e-36 | 5.19e-33 | 82 |
GO:00061199 | Breast | Precancer | oxidative phosphorylation | 53/1080 | 141/18723 | 1.15e-29 | 2.04e-26 | 53 |
GO:00090608 | Breast | Precancer | aerobic respiration | 58/1080 | 189/18723 | 5.69e-27 | 7.62e-24 | 58 |
GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
GO:00453338 | Breast | Precancer | cellular respiration | 59/1080 | 230/18723 | 5.97e-23 | 5.32e-20 | 59 |
GO:00159808 | Breast | Precancer | energy derivation by oxidation of organic compounds | 70/1080 | 318/18723 | 8.33e-23 | 6.37e-20 | 70 |
GO:00196468 | Breast | Precancer | aerobic electron transport chain | 34/1080 | 87/18723 | 3.95e-20 | 2.64e-17 | 34 |
GO:00427738 | Breast | Precancer | ATP synthesis coupled electron transport | 35/1080 | 95/18723 | 1.08e-19 | 5.76e-17 | 35 |
GO:00427758 | Breast | Precancer | mitochondrial ATP synthesis coupled electron transport | 35/1080 | 95/18723 | 1.08e-19 | 5.76e-17 | 35 |
GO:00229048 | Breast | Precancer | respiratory electron transport chain | 35/1080 | 114/18723 | 8.51e-17 | 3.26e-14 | 35 |
GO:00229008 | Breast | Precancer | electron transport chain | 42/1080 | 175/18723 | 1.37e-15 | 4.59e-13 | 42 |
GO:00061208 | Breast | Precancer | mitochondrial electron transport, NADH to ubiquinone | 19/1080 | 51/18723 | 2.05e-11 | 2.49e-09 | 19 |
GO:00102578 | Breast | Precancer | NADH dehydrogenase complex assembly | 19/1080 | 57/18723 | 1.93e-10 | 1.92e-08 | 19 |
GO:00329818 | Breast | Precancer | mitochondrial respiratory chain complex I assembly | 19/1080 | 57/18723 | 1.93e-10 | 1.92e-08 | 19 |
GO:00331088 | Breast | Precancer | mitochondrial respiratory chain complex assembly | 24/1080 | 93/18723 | 3.39e-10 | 3.16e-08 | 24 |
GO:00463946 | Breast | Precancer | carboxylic acid biosynthetic process | 32/1080 | 314/18723 | 1.30e-03 | 1.38e-02 | 32 |
GO:00723304 | Breast | Precancer | monocarboxylic acid biosynthetic process | 24/1080 | 214/18723 | 1.41e-03 | 1.48e-02 | 24 |
GO:00160536 | Breast | Precancer | organic acid biosynthetic process | 32/1080 | 316/18723 | 1.44e-03 | 1.50e-02 | 32 |
GO:00066335 | Breast | Precancer | fatty acid biosynthetic process | 19/1080 | 163/18723 | 2.74e-03 | 2.42e-02 | 19 |
GO:00516047 | Breast | Precancer | protein maturation | 28/1080 | 294/18723 | 6.45e-03 | 4.50e-02 | 28 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541514 | Liver | Cirrhotic | Diabetic cardiomyopathy | 108/2530 | 203/8465 | 1.99e-12 | 4.41e-11 | 2.72e-11 | 108 |
hsa0472314 | Liver | Cirrhotic | Retrograde endocannabinoid signaling | 57/2530 | 148/8465 | 1.45e-02 | 4.39e-02 | 2.71e-02 | 57 |
hsa0501215 | Liver | Cirrhotic | Parkinson disease | 158/2530 | 266/8465 | 3.62e-24 | 6.02e-22 | 3.71e-22 | 158 |
hsa0493232 | Liver | Cirrhotic | Non-alcoholic fatty liver disease | 106/2530 | 155/8465 | 2.16e-23 | 2.40e-21 | 1.48e-21 | 106 |
hsa0501615 | Liver | Cirrhotic | Huntington disease | 172/2530 | 306/8465 | 1.65e-22 | 1.10e-20 | 6.77e-21 | 172 |
hsa0502015 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa0501415 | Liver | Cirrhotic | Amyotrophic lateral sclerosis | 187/2530 | 364/8465 | 1.56e-18 | 6.50e-17 | 4.01e-17 | 187 |
hsa0019015 | Liver | Cirrhotic | Oxidative phosphorylation | 83/2530 | 134/8465 | 1.03e-14 | 3.44e-13 | 2.12e-13 | 83 |
hsa0520832 | Liver | Cirrhotic | Chemical carcinogenesis - reactive oxygen species | 121/2530 | 223/8465 | 1.35e-14 | 4.08e-13 | 2.52e-13 | 121 |
hsa0502215 | Liver | Cirrhotic | Pathways of neurodegeneration - multiple diseases | 217/2530 | 476/8465 | 7.30e-14 | 2.03e-12 | 1.25e-12 | 217 |
hsa0501015 | Liver | Cirrhotic | Alzheimer disease | 180/2530 | 384/8465 | 5.52e-13 | 1.36e-11 | 8.36e-12 | 180 |
hsa0471415 | Liver | Cirrhotic | Thermogenesis | 121/2530 | 232/8465 | 5.70e-13 | 1.36e-11 | 8.36e-12 | 121 |
hsa0541515 | Liver | Cirrhotic | Diabetic cardiomyopathy | 108/2530 | 203/8465 | 1.99e-12 | 4.41e-11 | 2.72e-11 | 108 |
hsa0472315 | Liver | Cirrhotic | Retrograde endocannabinoid signaling | 57/2530 | 148/8465 | 1.45e-02 | 4.39e-02 | 2.71e-02 | 57 |
hsa0501222 | Liver | HCC | Parkinson disease | 198/4020 | 266/8465 | 9.40e-20 | 1.58e-17 | 8.76e-18 | 198 |
hsa0501622 | Liver | HCC | Huntington disease | 219/4020 | 306/8465 | 3.06e-18 | 3.42e-16 | 1.90e-16 | 219 |
hsa0501422 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
hsa0520842 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
hsa0493242 | Liver | HCC | Non-alcoholic fatty liver disease | 124/4020 | 155/8465 | 4.54e-17 | 2.54e-15 | 1.41e-15 | 124 |
hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NDUFAB1 | SNV | Missense_Mutation | c.286G>A | p.Glu96Lys | p.E96K | O14561 | protein_coding | tolerated(0.06) | benign(0.1) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
NDUFAB1 | SNV | Missense_Mutation | novel | c.194N>A | p.Cys65Tyr | p.C65Y | O14561 | protein_coding | tolerated(0.15) | benign(0.009) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
NDUFAB1 | SNV | Missense_Mutation | c.231G>C | p.Glu77Asp | p.E77D | O14561 | protein_coding | tolerated(0.3) | benign(0.005) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
NDUFAB1 | SNV | Missense_Mutation | novel | c.461T>C | p.Val154Ala | p.V154A | O14561 | protein_coding | deleterious(0.04) | probably_damaging(0.987) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
NDUFAB1 | SNV | Missense_Mutation | c.136G>A | p.Gly46Arg | p.G46R | O14561 | protein_coding | tolerated(0.26) | benign(0.001) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NDUFAB1 | SNV | Missense_Mutation | rs776920868 | c.256N>A | p.Val86Ile | p.V86I | O14561 | protein_coding | tolerated(0.08) | possibly_damaging(0.647) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
NDUFAB1 | SNV | Missense_Mutation | rs75847980 | c.301N>G | p.Asn101Asp | p.N101D | O14561 | protein_coding | tolerated(0.38) | benign(0.001) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
NDUFAB1 | SNV | Missense_Mutation | novel | c.218N>A | p.Pro73His | p.P73H | O14561 | protein_coding | deleterious(0) | benign(0.336) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
NDUFAB1 | SNV | Missense_Mutation | novel | c.212T>C | p.Met71Thr | p.M71T | O14561 | protein_coding | tolerated(0.48) | benign(0) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NDUFAB1 | SNV | Missense_Mutation | c.322N>A | p.Leu108Met | p.L108M | O14561 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4706 | NDUFAB1 | NA | inhibitor | CHEMBL3545320 | ME-344 | |
4706 | NDUFAB1 | NA | inhibitor | CHEMBL1703 | METFORMIN HYDROCHLORIDE | |
4706 | NDUFAB1 | NA | inhibitor | CHEMBL3545135 | NV-128 |
Page: 1 |